SCHEMBL206513

SCHEMBL206513

O=C(O)C12CCC(c3ccc(Br)cc3)(CC1)CC2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 3/20 0.46
SOAT1 P35610 3/20 0.46
MAPT P10636 1/20 0.40
PNMT P11086 1/20 0.39
CES2 O00748 1/20 0.35
CES1 P23141 1/20 0.35
MAPK1 P28482 2/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PTGFR P43088 4/20 0.34
OPRM1 P35372 1/20 0.34
OPRD1 P41143 1/20 0.34
OPRK1 P41145 1/20 0.34
OPRL1 P41146 1/20 0.34
HDAC1 Q13547 2/20 0.34
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31095736 0.83 DGAT1 (0.39) DGAT1SOAT1MAPTPNMTCES2
SCHEMBL16407785 0.83 MAPT (0.39) DGAT1SOAT1MAPTPNMTCES2
SCHEMBL31095821 0.83 MAPT (0.42) DGAT1SOAT1MAPTPNMTCES2
SCHEMBL23531198 0.82 MAPT (0.37) DGAT1SOAT1MAPTCES2CES1
SCHEMBL2452042 0.82 PNMT (0.59) DGAT1SOAT1PNMTLMNAOPRM1
SCHEMBL206706 0.80 GSK3B (0.40) DGAT1SOAT1MAPTPNMTCES2
SCHEMBL204803 0.79 CHRM1 (0.39) DGAT1SOAT1MAPTMAPK1ALDH1A1
SCHEMBL207081 0.79 ALDH1A1 (0.41) DGAT1SOAT1PNMTALDH1A1SMN1; SMN2
SCHEMBL16730751 0.79 MAPT (0.36) DGAT1SOAT1MAPTPNMTCES2
SCHEMBL13132754 0.79 MEN1 (0.37) DGAT1SOAT1MAPTPNMTCES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680247-A1 DPP1 INHIBITORS WITH POLYCYCLIC LINKERS AND USES THEREOF Insmed Incorporated (US) 2026-01-21 EP disclosed
WO-2025108255-A1 POLYCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海齐鲁制药研究中心有限公司 2025-05-30 WO disclosed
WO-2024192416-A1 DPP1 INHIBITORS WITH POLYCYCLIC LINKERS AND USES THEREOF INSMED INCORPORATED (US) 2024-09-19 WO disclosed
EP-3681883-B1 DIPHENYL DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2024-02-21 EP disclosed
CN-111094278-B Diphenyl derivative and use thereof 诺华股份有限公司 2023-07-14 CN disclosed
EP-3681883-A1 DIPHENYL DERIVATIVES AND USES THEREOF Novartis AG (CH) 2020-07-22 EP disclosed
US-10633350-B2 Diphenyl derivatives and uses thereof NOVARTIS AG (CH) 2020-04-28 US disclosed
EP-3626716-A1 ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2020-03-25 EP disclosed
WO-2019053090-A1 DIPHENYL DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2019-03-21 WO disclosed
US-20190077773-A1 DIPHENYL DERIVATIVES AND USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2019-03-14 US disclosed
US-20120157404-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-06-21 US disclosed
EP-2430014-A1 ANTIVIRAL COMPOUNDS Gilead Sciences, Inc. (US) 2012-03-21 EP disclosed
US-8088368-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2012-01-03 US disclosed
US-8088368-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2012-01-03 US disclosed
US-8088368-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2012-01-03 US disclosed
US-20100310512-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2010-12-09 US disclosed
US-20100310512-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2010-12-09 US disclosed
US-20100310512-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2010-12-09 US disclosed
WO-2010132601-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2010-11-18 WO disclosed
WO-2010132601-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2010-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077773-A1 DIPHENYL DERIVATIVES AND USES THEREOF MYOF, NGF, MUSK DGAT1 2993/4885SOAT1 4118/4885MAPT 2084/4885
US-20120157404-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 DGAT1 1501/4885SOAT1 2974/4885MAPT 2923/4885
US-10633350-B2 Diphenyl derivatives and uses thereof MYOF, NGF, MUSK DGAT1 2993/4885SOAT1 4118/4885MAPT 2084/4885
US-20100310512-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 DGAT1 1501/4885SOAT1 2974/4885MAPT 2923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.